



213.1152-CIP

-Q(CR₅₀R₅₁)_q-,-Q(CR₅₀R₅₁)_qO(CR₅₂R₅₃)_r-Q(CH₂CH₂O)_q(CR₅₂R₅₃)_r-,-QCR₅₀R₅₁)_qNHC(O)(CR₅₂R₅₃)_r-,

and

-Q(CH₂)_q-S-S-(CH₂)_r-; andL₂ is selected from the group consisting of:-(CR₅₀R₅₁)_qQ'-,-(CR₅₂R₅₃)_rO(CR₅₀R₅₁)_qQ'--(CR₅₂R₅₃)_r(OCH₂CH₂)Q'-,-(CR₅₂R₅₃)_rC(O)NH(CR₅₀R₅₁)_qQ'-,

and


-(CH₂)_q-S-S-(CH₂)_rQ-whereinQ and Q' are independently selected from O, S or NH;R₅₀₋₅₃ and R_{50'-53'} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyls, C₃₋₁₂ branched alkyls, C₃₋₈ cycloalkyls, C₁₋₆ substituted alkyls, C₃₋₈ substituted cyloalkyls, aryls substituted aryls, aralkyls,C₁₋₆ heteroalkyls, substituted C₁₋₆ heteroalkyls, C₁₋₆ alkoxy, phenoxy andC₁₋₆ heteroalkoxy;R₅₄ and R_{54'} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyls, C₃₋₁₂ branched alkyls, C₃₋₈ cycloalkyls, C₁₋₆ substituted alkyls, C₃₋₈ substituted cyloalkyls, aryls substituted aryls, aralkyls,C₁₋₆ heteroalkyls, substituted C₁₋₆ heteroalkyls, C₁₋₆ alkoxy, phenoxy,

213.1152-CIP


C₁₋₆ heteroalkoxy, NO₂, haloalkyl and halogen; and

q' and r' are each a positive integer.

2. (currently amended) The prodrug of claim 1, wherein said nucleotide is selected from the group consisting of



213.1152-CIP



wherein

M is O or S;

B₁ and B₂ are independently selected from the group consisting of A (adenine), G (guanine), C (cytosine), T (thymine), U (uracil) and modified bases; R₁₀₀ and R₁₀₁ are independently selected from the group consisting of H, OR' where R' is H, a C₁₋₆ alkyl, substituted alkyls, nitro, halo and aryl


3. (previously presented) The prodrug of claim 1, wherein said oligonucleotide is contains from about 10 to about 1000 nucleotides.
4. (previously presented) The prodrug of claim 1, wherein M is S.
5. (currently amended) The prodrug of claim 1, wherein the oligonucleotide residue is a phosphorthioate oligonucleotide residue.
6. (previously presented) The prodrug of claim 1, wherein said oligonucleotide residue is an antisense oligonucleotide residue or oligodeoxynucleotide residue.
7. (currently amended) The prodrug of claim 6, wherein said antisense oligonucleotide residue or

213.1152-CIP

oligodeoxynucleotide residue is selected from the group consisting of, oligonucleotides and oligodeoxynucleotides with phosphodiester backbones or phosphorothioate backbones, LNA, PNA, tricyclo-DNA, decoy ODN, [[RNAi,]], ribozymes, spiegelmers, and CpG oligomers.

8. (currently amended) The prodrug of claim 6, wherein said antisense oligonucleotide has a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, wherein $[[X]]_n$ of SEQ ID NO: 4 is any compatible nucleotide.


9. (previously presented) The prodrug of claim 1, wherein at least one of R_1 and R_2 is a polymeric residue having a capping group A, selected from the group consisting of OH, NH_2 , SH, CO_2H , C_{1-6} alkyls,




(III)

wherein X_2 and X_3 are independently selected nucleotide or oligonucleotide residues.


10. (previously presented) A prodrug of claim 9, selected from the group consisting of:



bis-3'-oligonucleotide,




bis-5'-oligonucleotide,



bis-5', 3'-oligonucleotide,


and



213.1152-CIP


(iv)
bis-3', 5'-oligonucleotide.

11. (currently amended) The prodrug of claim 1 wherein L_4 is selected from the group consisting of:



and

213.1152-CIP



wherein:

Y_{1-25} are independently selected from the group consisting of O, S or NR_9 ;

R_{6-7} , R_{9-13} , R_{16-25} , and R_{27-41} are independently selected from the group consisting of hydrogen, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} heteroalkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy;

Ar is a moiety which forms a multi-substituted aromatic hydrocarbon or a multi-substituted heterocyclic group;

L_{5-12} are independently selected bifunctional spacers;

~~Z is selected from among moieties actively transported into a target cell, hydrophobic moieties, bifunctional linking moieties and combinations thereof;~~


c, h, k, l, r, s, v, w, v', w', c', and h' are independently selected positive integers;

a, e, g, j, t, z, a', z', e' and g' are independently either zero or a positive integer; and

b, d, f, i, u, q, b', d' and f' are independently zero or one.


12. (previously presented) The prodrug of claim 1 wherein L_1 is selected from the group consisting of:

213.1152-CIP



and

213.1152-CIP



wherein,

$Y_{1'}$, $Y_{25'}$ are independently selected from the group consisting of O, S or NR_9 ;


$R_{6'-7'}$, $R_{9'-13'}$, $R_{16'-25'}$, and $R_{27'-41'}$ are independently selected from the group consisting of hydrogen, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} heteroalkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy; and

$L_{5'-12'}$ are independently selected bifunctional spacers.

13. (previously presented) The prodrug of claim 1 wherein R_{1-2} are each polyalkylene oxides.

14. (previously presented) The prodrug of claim 1 wherein R_{1-2} are each polyethylene glycols.

15. (previously presented) The prodrug of claim 1 wherein R_{1-2} are independently selected from the group consisting of:



wherein


213.1152-CIP

n' is the degree of polymerization;

R_{48} is selected from the group consisting of hydrogen, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} heteroalkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy; and

J is a capping group.

16. (previously presented) The prodrug of claim 1, wherein R_{1-2} are independently




wherein x is a positive integer selected so that the weight average molecular weight is at least about 2,000 Da to about 136,000 Da.

17. (previously presented) The prodrug of claim 1, wherein R_{1-2} independently have a weight average molecular weight of from about 3,000 Da to about 100,000 Da.

18. (previously presented) The prodrug of claim 1, wherein R_{1-2} independently have a weight average molecular weight of from about 5,000 Da to about 40,000 Da.

19. (previously presented) The prodrug of claim 8, wherein said antisense oligonucleotide is oblimersen (SEQ ID NO: 1).

20. (withdrawn) An oligonucleotide prodrug of the formula:



(v)

wherein:





L_2 is a spacing group;

X_1 is a nucleotide or an oligonucleotide residue;

u' is a positive integer; and

T is a member of the group consisting of:

213.1152-CIP




and


wherein:

 D' is one of

213.1152-CIP




213.1152-CIP




and wherein R_{61} is a polymer residue.

21. (currently amended) A compound of claim 1 selected from the group consisting of:



213.1152-CIP

[[and]]



all of which comprise an oligonucleotide of SEQ ID NO: 1.

22. (withdrawn) A method of making a prodrug comprising:

reacting a compound of the formula:

R_2 - L_4 -leaving group

with a compound of the formula:

H - L_3 - X_1

under conditions sufficient to form a prodrug of the formula

R_2 - L_4 - L_3 - X_1 ,

wherein:

R_2 is a polymer residue;

L_4 is a releasable linking moiety;

L_3 is a spacing group;

X_1 is a nucleotide or an oligonucleotide residue.

23. (withdrawn) A method of treating a mammal, comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1.

24. (withdrawn) The method of claim 23, wherein the mammal is being treated for cancer.

25. (withdrawn) The method of claim 23, wherein X_1 is an antisense oligonucleotide.

26. (withdrawn) The method of claim 23 wherein the mammal is also treated with a second anticancer agent that is administered simultaneously or sequentially with the oligonucleotide prodrug.